Shu-Min Xiong

Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Zhixiang Shen, Guoqiang Chen, Jian-Hua Ni et al. · Blood · 1997 · 1.4K citations

Medicine, Pharmacokinetics, Pharmacology +17

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Guoqiang Chen, Xuegeng Shi, Wei Tang et al. · PubMed · 1997 · 803 citations

Medicine, Hematology, Oncology +14

Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients

Chao Niu, Hua Yan, Ting Yu et al. · Blood · 1999 · 627 citations

Medicine, Hematology, Oncology +17

<i>AML1-ETO</i> and <i>C-KIT</i> mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec

Yueying Wang, Guang‐Biao Zhou, Tong Yin et al. · Proceedings of the National Academy of Sciences · 2005 · 277 citations · Full text

Medicine, Genetics, Oncology +17

<i>NOTCH1</i> Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis

Yongmei Zhu, Weili Zhao, Jianfei Fu et al. · Clinical Cancer Research · 2006 · 151 citations

Medicine, Hematology, Oncology +16